Generate Biomedicines
Company Snapshot
Generate Biomedicines is a clinical-stage generative biology company that leverages artificial intelligence to design and develop therapeutics. The company utilizes its proprietary Generate Platform, which integrates computational innovations with scalable biohardware, to create solutions for complex biological challenges. Their key value proposition lies in their ability to engineer proteins and therapeutics through both reference-based and de novo design approaches.
Key Financials
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $31.9M | $31.9M | $20.5M |
| YoY Growth | +0.0% | +55.6% | - |
| Adjusted Net Loss | -$223.0M | -$223.0M | -$181.4M |
| Margin % | -699.1% | -699.1% | -884.9% |
Balance Sheet
Implied Valuation at Midpoint
Based on price range midpoint and most recent fiscal year data.
S-1 Highlights
Market & Competition
The company operates within the biotechnology industry, facing competition from other firms utilizing AI for drug engineering, including companies based in China that benefit from significant government investment and access to extensive biological datasets. The company competes with various biotechnology firms that may have more resources and advanced methodologies.
Use of Proceeds
Proceeds from the IPO are expected to be used to advance the company's clinical programs and further develop their Generate Platform.
Key Risk Factors
- ●The company faces competition from biotechnology companies in China that may develop and deploy advanced drug discovery technologies more rapidly and at lower costs.
- ●There are risks associated with the quality and security of AI outputs, which could adversely affect the company's business and operations.
Deal Structure
Reported Broker Availability
Reported by users or publicly disclosed. Information is for reference only.